- Note. S = screening; B (T1) = baseline assessment; T2 = 6–8 weeks after start of the treatment; T3 = 12–16 weeks after start of the treatment; F1 = 24 weeks after start of the treatment; F2 = 52 weeks after start of the treatment
- BDI-II Beck Depression Inventory II; CAPS-5 Clinician Administered PTSD Scale for DSM-5; DAQ Depressive Attributions Questionnaire; DES-T Dissociative Experiences Scale Taxon; EMDR eye movement desensitization and reprocessing; EQ-5D-5L 5-level EuroQol 5D version; ImRs imagery rescripting; ITQ International Trauma Questionnaire; LEC-5 Life Events Checklist for DSM-5; MHQoL-7D Mental Health Quality of Life seven-dimensional Questionnaire; PCL-5 PTSD Checklist for DSM-5; PTCI Posttraumatic Cognitions Inventory; SCL-90-R H Symptom Checklist-90-Revised Hostility subscale; SCID-5-CV Structured Clinical Interview for the DSM-5 Disorders-Clinician Version; SCID-5-PD Structured Clinical Interview for the DSM-5 Personality Disorders; SECS Self-Expression and Control Scale; WHODAS 2.0 WHO Disability Assessment Schedule 2.0
- 1An additional assessment (waitlist assessment) is conducted if patients have a waitlist period of more than 5 weeks before the start of treatment
- 2Consisting of an assessment of the DSM-5 disorders, lifetime exposure to traumatic events, index trauma, traumatic memory, and encapsulated belief
- 3Extended with seven additional items. In addition to the standard assessments, the PCL-5 is also completed before every treatment session, starting with session 2
- 4A brief version of the semi-structured demographic interview including questions about the employment situation, medication use, substance use, and use of psychological treatments other than the study treatment
- 5This test for patients and therapists is assessed before the fourth and eighth treatment session
- 6These items are completed before every treatment session, starting with session 2, by the patient and therapist
